AtlasVector
Launch AtlasVector →
CRVO2.24-0.27 (-10.76%) session● PRIOR SESSION CLOSE
AtlasVector › Decision Feed › CRVO

CRVOcited research thesis

CRVO — what changed and why it matters

House verdict · CRVO · multi-desk debate + self-falsification

No sealed verdict on CRVO yet

No debate has been run on CRVO; debates rotate through a watchlist. The conviction call below is the signal engine’s output — one input to a debate, not a multi-desk verdict. Sealed debates on other names, each with its falsification check, are available.
Open the Glass Box →
Individual · $49 a monthThe conviction call on CRVO — outside the public coverage list

Covered names include the conviction call in the sealed record at no charge. CRVO is outside public coverage; running the signal engine on it requires a seat. The panels above do not depend on it.

Start checkout →
synthetic0 of 17 figures below re-derived from a sourcewritten 2026-07-27

This thesis is 78 days old. Statements below are as of 2026-07-27.

CRVO — what moved and why today

Context (knowledge graph)

AtlasVector tracks 12 related entities for CRVO in its knowledge graph. [c1]

Catalyst confluence

  • Catalyst

What changed

  • HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target
  • CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
  • CervoMed Presents New Insights Into Neflamapimod's Treatment Effects In Dementia with Lewy Bodies At The Alzheimer's Association International Conference 2026

Valuation spine (rich/cheap)

Rich/cheap deviation: -1.077. Conviction signal: 1.225. [c6]

Key takeaways
  • HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target
  • CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
  • CervoMed Presents New Insights Into Neflamapimod's Treatment Effects In Dementia with Lewy Bodies At The Alzheimer's Association International Conference 2026
Headlines · CRVO UNAVAILABLE

The headline tape could not be read, so no articles are shown. Nothing is written in their place.

Provenance

verdicts, debates and hash-chained audit seals recorded against CRVO
Instruments 1
  • CRVO2026-10-07
Session bars 5
  • CRVO · Wed Oct 07 session barCRVO2026-10-07
  • CRVO · Tue Oct 06 session barCRVO2026-10-06
  • CRVO · Mon Oct 05 session barCRVO2026-10-05
  • CRVO · Fri Oct 02 session barCRVO2026-10-02
  • CRVO · Thu Oct 01 session barCRVO2026-10-01
Screen metrics 1
  • CRVO · screen metrics · Wed Oct 07CRVO2026-10-07

7 recorded entities · 6 links. synthetic = the row is flagged as built on synthetic inputs; no provenance = the store holds no synthetic flag for the row. Unmarked rows are flagged non-synthetic. Chain seals list sequence number, event key and SHA-256 chain hash. Verify seal opens the verdict's proof panel, where the sealed record is re-hashed in the browser and compared against the seal.

Cited sources · 6

[c1]AtlasVector knowledge graphgraph context for CRVO
[c2]CatalystCatalyst
[c3]NewswireHC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target
[c4]NewswireCervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
[c5]NewswireCervoMed Presents New Insights Into Neflamapimod's Treatment Effects In Dementia with Lewy Bodies At The Alzheimer's Association International Conference 2026
[c6]AtlasVector valuation spineconsensus valuation

The full record is in AtlasVector.

Standing monitors, multi-desk debate, audited paper trading and a persistent research record.

Open AtlasVector →